Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of NovoCure Ltd (NASDAQ: NVCR) was $15.73 for the day, down -2.36% from the previous closing price of $16.11. In other words, the price has decreased by -$2.36 from its previous closing price. On the day, 0.72 million shares were traded. NVCR stock price reached its highest trading level at $16.16 during the session, while it also had its lowest trading level at $15.64.
Ratios:
Our analysis of NVCR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.49. In the meantime, Its Debt-to-Equity ratio is 1.87 whereas as Long-Term Debt/Eq ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on October 16, 2024, Upgraded its rating to Buy and sets its target price to $30 from $24 previously.
H.C. Wainwright Downgraded its Buy to Neutral on August 28, 2023, whereas the target price for the stock was revised from $85 to $25.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 02 ’24 when Paravasthu Mukund sold 44 shares for $16.69 per share. The transaction valued at 734 led to the insider holds 3,459 shares of the business.
Puri Michal Nath sold 810 shares of NVCR for $12,792 on Oct 31 ’24. The Chief Human Resources Officer now owns 110,093 shares after completing the transaction at $15.79 per share. On Nov 01 ’24, another insider, Leonard Frank X, who serves as the EVP, Pres., Novocure Oncology of the company, sold 598 shares for $15.94 each. As a result, the insider received 9,531 and left with 161,236 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVCR now has a Market Capitalization of 1702001664 and an Enterprise Value of 1458853120. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.86 while its Price-to-Book (P/B) ratio in mrq is 4.71. Its current Enterprise Value per Revenue stands at 2.525 whereas that against EBITDA is -10.375.
Stock Price History:
The Beta on a monthly basis for NVCR is 0.67, which has changed by 0.31725264 over the last 52 weeks, in comparison to a change of 0.2936039 over the same period for the S&P500. Over the past 52 weeks, NVCR has reached a high of $24.74, while it has fallen to a 52-week low of $11.29. The 50-Day Moving Average of the stock is -4.90%, while the 200-Day Moving Average is calculated to be -7.91%.
Shares Statistics:
NVCR traded an average of 1.05M shares per day over the past three months and 903860 shares per day over the past ten days. A total of 107.08M shares are outstanding, with a floating share count of 97.35M. Insiders hold about 10.03% of the company’s shares, while institutions hold 85.89% stake in the company. Shares short for NVCR as of 1730332800 were 5956142 with a Short Ratio of 5.69, compared to 1727654400 on 5488718. Therefore, it implies a Short% of Shares Outstanding of 5956142 and a Short% of Float of 6.5799996.
